3.24
Malattia di Parkinson II: Fisiopatologia
La malattia di Parkinson, o MP, è una malattia neurodegenerativa progressiva che interessa principalmente il movimento, con ulteriori manifestazioni n…
La malattia di Parkinson, o PD, è caratterizzata dalla progressiva degenerazione dei neuroni dopaminergici nella substantia nigra pars compacta.
Questa perdita neuronale porta a una marcata riduzione dei livelli di dopamina all'interno dello striato, disturbando il circuito dei gangli della base coinvolto nel controllo motorio.
Lo squilibrio risultante si manifesta clinicamente come tremore a riposo, spesso descritto come un tremore da rollo di pillole, insieme a rigidità muscolare, bradicinesia e instabilità posturale.
Un'altra caratteristica patologica distintiva della PD è il dispiegamento e l'aggregazione della α-sinucleina, una proteina neuronale presinaptica.
Questi aggregati proteici si accumulano come inclusioni intracellulari note come corpi di Lewy.
L'accumulo di α-sinucleina interrompe molteplici processi cellulari, tra cui il traffico delle vescicole e la funzione mitocondriale.
Inoltre, la α-sinucleina mal ripiegata può propagarsi tra i neuroni in modo simile a un prione, contribuendo alla progressiva diffusione della patologia.
Insieme, la neurodegenerazione dopaminergica e l'aggregazione α-sinucleina guidano le caratteristiche cliniche e la progressione della DP.
View the full transcript and gain access to JoVE Core videos
Q1: What causes the motor symptoms in Parkinson disease?
Parkinson disease results from progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced dopamine in the striatum. This dopamine loss disrupts basal ganglia circuitry controlling movement, causing resting tremor, muscular rigidity, bradykinesia, and postural instability. The imbalance between direct and indirect motor pathways produces these characteristic motor deficits.
Q2: What are Lewy bodies and how do they form in Parkinson disease?
Lewy bodies are intracellular inclusions composed of misfolded and aggregated α-synuclein, a presynaptic neuronal protein. These protein aggregates accumulate within neurons and disrupt critical cellular processes including vesicle trafficking and mitochondrial function. The formation and spread of Lewy bodies contribute significantly to neuronal dysfunction and disease progression.
Q3: How does α-synuclein contribute to Parkinson disease progression?
Misfolded α-synuclein aggregates disrupt multiple cellular processes and may propagate between neurons in a prion-like fashion, spreading pathology throughout the brain. This protein-to-protein transmission mechanism drives progressive neurodegeneration beyond the initial dopaminergic neuron loss. The combination of local cellular damage and trans-neuronal spread accelerates disease advancement.
Q4: What role does mitochondrial dysfunction play in Parkinson disease?
Mitochondrial impairment, including reduced complex I activity and defective mitophagy, leads to accumulation of damaged mitochondria and increased reactive oxygen species. Environmental toxins such as MPTP and rotenone selectively inhibit mitochondrial function, promoting neuronal death. This oxidative stress contributes to selective vulnerability of dopaminergic neurons in the substantia nigra.
Q5: How do genetic mutations affect protein clearance in Parkinson disease?
Mutations in genes like PINK1, Parkin, and GBA impair the ubiquitin-proteasome and autophagy-lysosomal systems responsible for clearing toxic proteins. Defective protein clearance allows accumulation of misfolded α-synuclein and other damaged proteins. These genetic alterations in muscle tone and motor control pathways interconnect with broader pathological mechanisms driving neurodegeneration.
Q6: What is the relationship between neuroinflammation and Parkinson disease pathology?
Activated microglia release cytokines and reactive oxygen species that worsen neuronal injury in Parkinson disease. The Braak hypothesis proposes that α-synuclein spreads from peripheral sites to the brain, triggering progressive neuroinflammation. This immune activation amplifies dopaminergic neuron loss and accelerates disease progression.
Q7: How do environmental toxins contribute to Parkinson disease development?
Environmental toxins such as MPTP and rotenone selectively inhibit mitochondrial complex I function, mimicking aspects of Parkinson disease pathology. These exposures generate oxidative stress and promote neuronal death in dopaminergic populations. Combined with genetic susceptibility, environmental toxins contribute to interconnected pathological pathways driving disease onset and progression.